After finishing at $27.95 in the prior trading day, PTC Therapeutics Inc (NASDAQ: PTCT) closed at $28.31, up 1.29%. In other words, the price has increased by $+0.36 from its previous closing price. On the day, 823161 shares were traded. PTCT stock price reached its highest trading level at $28.66 during the session, while it also had its lowest trading level at $27.61.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of PTCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.10.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $37.
Oppenheimer Upgraded its Perform to Outperform on October 30, 2023, while the target price for the stock was maintained at $165.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 30 when Boulding Mark Elliott sold 794 shares for $27.25 per share. The transaction valued at 21,637 led to the insider holds 71,189 shares of the business.
Almstead Neil Gregory sold 618 shares of PTCT for $16,841 on Jan 30. The CHIEF TECHNICAL OPS OFFICER now owns 61,202 shares after completing the transaction at $27.25 per share. On Jan 30, another insider, Pauwels Eric, who serves as the CHIEF BUSINESS OFFICER of the company, sold 366 shares for $27.25 each. As a result, the insider received 9,974 and left with 44,181 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 2.14B and an Enterprise Value of 2.55B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.68. Its current Enterprise Value per Revenue stands at 3.19 whereas that against EBITDA is -6.00.
Stock Price History:
Over the past 52 weeks, PTCT has reached a high of $59.84, while it has fallen to a 52-week low of $17.53. The 50-Day Moving Average of the stock is 27.16, while the 200-Day Moving Average is calculated to be 32.42.
Shares Statistics:
The stock has traded on average 1.09M shares per day over the past 3-months and 909.78k shares per day over the last 10 days, according to various share statistics. A total of 73.10M shares are outstanding, with a floating share count of 72.56M. Insiders hold about 3.85% of the company’s shares, while institutions hold 112.19% stake in the company. Shares short for PTCT as of Jan 31, 2024 were 11.04M with a Short Ratio of 10.13, compared to 9.78M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 14.63% and a Short% of Float of 19.82%.
Earnings Estimates
Its stock is currently analyzed by 13 different market analysts. On average, analysts expect EPS of $0.5 for the current quarter, with a high estimate of $1.47 and a low estimate of -$1.1, while EPS last year was -$2.35. The consensus estimate for the next quarter is -$1.44, with high estimates of -$0.56 and low estimates of -$2.66.
Analysts are recommending an EPS of between -$4.84 and -$7.41 for the fiscal current year, implying an average EPS of -$5.88. EPS for the following year is -$6.23, with 13 analysts recommending between -$2.84 and -$9.97.
Revenue Estimates
11 analysts predict $321.29M in revenue for the current quarter. It ranges from a high estimate of $354.24M to a low estimate of $312.8M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $167.41M, an estimated increase of 91.90% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $162.19M, a decrease of -26.40% less than the figure of $91.90% in the same quarter last year. There is a high estimate of $183.5M for the next quarter, whereas the lowest estimate is $143.5M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $958.11M, while the lowest revenue estimate was $919M, resulting in an average revenue estimate of $945.21M. In the same quarter a year ago, actual revenue was $698.8M, up 35.30% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $612.29M in the next fiscal year. The high estimate is $808.07M and the low estimate is $446M. The average revenue growth estimate for next year is down -35.20% from the average revenue estimate for this year.
